The basis of this article is to provide:
1. A brief overview of about Akorn Inc.
2. An analysis of Akorn's core business
3. Evaluation of sales, market/sector, and financials (2013 Q1 and Q2)
4. Opinionated conclusions and price targets
Akorn Inc. (NASDAQ: AKRX)
Akorn Inc. ("Akorn," "AKRX" or the "Company") is a generic pharmaceutical company with a market cap of roughly $1.6 billion (at time of writing). A quick analysis of Akorn reveals that the company has experienced substantial revenue growth over the past three years. Subsequently, Akorn has increased its share price from the $1.80 range to the $16 range (a total return of roughly 789%). Despite the significant increase in valuation, Akorn still remains...
Only subscribers can access this article, which is part of the PRO research library covering 3,580 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: